Pliva Divests Sanctura, Cites Lack Of Resources To Support The Incontinence Agent

The overactive bladder therapy is the first product to be divested as part of a strategic realignment under which Pliva will exit the brand business. The company says brand products are not meeting expectations, and the resources needed are higher than once expected.